IceCure Medical (ICCM) investor relations material

Company overview and business model

• Commercial-stage medical device company specializing in cryoablation systems using liquid nitrogen for tumor treatment, offering minimally invasive alternatives to surgery for various tumor types including breast, lung, kidney, and bone.

• Lead product, ProSense system, is FDA-authorized for local treatment of low-risk breast cancer in women aged 70+ with adjuvant endocrine therapy.

• Incorporated in Israel, listed on both the Tel Aviv Stock Exchange and Nasdaq, and operates as a foreign private issuer with reduced reporting requirements.

• Benefits from emerging growth company status, allowing exemptions from certain U.S. public company requirements for up to five years or until specific financial thresholds are met.

Financial performance and metrics

• As of December 31, 2025: $8.9 million in cash and cash equivalents, $9.1 million in total shareholders' equity, and an accumulated deficit of $120.4 million.

• 73,122,293 Ordinary Shares issued and outstanding as of December 31, 2025.

• Additional potential dilution from options, restricted share units, and warrants outstanding.

Use of proceeds and capital allocation

• Net proceeds from securities sales intended for general corporate and working capital purposes, including operations, capital expenditures, and R&D.

• Specific uses for each offering to be detailed in the relevant prospectus supplement.